SCHOTT Pharma AG & Co. KGaA
ISIN: DE000A3ENQ51
WKN: A3ENQ5
26 September 2024 12:30PM

EQS-News: SCHOTT Pharma, Gerresheimer, and Stevanato Group announce strategic industry “Alliance for RTU”

SCHOTT Pharma AG & Co. KGaA · ISIN: DE000A3ENQ51 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 1995693

EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): Agreement
SCHOTT Pharma, Gerresheimer, and Stevanato Group announce strategic industry “Alliance for RTU”

26.09.2024 / 12:30 CET/CEST
The issuer is solely responsible for the content of this announcement.


SCHOTT Pharma, Gerresheimer, and Stevanato Group announce strategic industry “Alliance for RTU”

  • Market advances adoption of ready-to-use containers
  • Improved operational efficiency in pharmaceutical manufacturing processes
  • Increased patient safety with high-quality sterile primary packaging

SCHOTT Pharma AG & Co. KGaA (MDAX: 1SXP), a pioneer in pharma drug containment solutions and delivery systems, together with Gerresheimer AG (MDAX: GXI) and Stevanato Group S.p.A. (NYSE: STVN), announced today that they have entered into a strategic industry alliance ("Alliance for RTU") to support market adoption of Ready-to-Use (RTU) vials and cartridges.

The Alliance for RTU aims to share with pharmaceutical companies, CMOs and CDMOs expertise and technical knowledge in high-quality sterile primary packaging, specifically ready-to-fill vials and cartridges, highlighting RTU configurations' advantages over conventional bulk packaging.

Reduced risk and lower total cost of ownership
Traditional fill-and-finish processes present several operational risks and require increased efficiency. By adopting an industrial ready-to-use (RTU) setup, pharmaceutical companies and Contract Manufacturing Organizations (CMOs) can benefit from reduced operational risks, enhanced flexibility and efficiency, and lower waste. RTU technology can help streamline processes, increase productivity, and thus lower total cost of ownership (TCO) while reducing contamination risks and easing EU GMP Annex 1 compliance.

Pharmaceutical companies, CMOs and CDMOs opting for ready-to-use containers also can benefit from higher-quality products, which helps minimize the release of glass particles and risks of breakage or rejection while preserving the drug inside throughout its entire life cycle.

Open expert platform for RTU industry standard
Additionally, the market is driving investment in advanced aseptic filling technologies due to increasing demand for injectable medicines and regulatory pressure to meet safety standards. In this context, the Alliance for RTU aims to create an expert platform open to other industry players to help industry manufacturers learn about the key benefits of RTU processes and products and to better evaluate investments for transitioning to efficient filling systems and meeting their unique needs from clinical applications to widespread commercial use.

“The shift towards ready-to-use vials and cartridges reflects a collective industry move to advance quality and efficiency in aseptic filling processes and this alliance shows readiness by expanding capacity and thereby supporting this market trend,” said Andreas Reisse, CEO at SCHOTT Pharma. “Ready-to-use solutions can reduce complexities and better meet the stringent requirements of modern pharmaceutical production.”

“RTU vials and cartridges represent a significant advancement in product quality, offering enhanced reliability and efficiency in pharmaceutical processes. This alliance allows us to highlight further how RTU solutions elevate standards across the industry, ensuring safer and more effective delivery of medications to patients worldwide," said Franco Stevanato, CEO at Stevanato Group.

"As an industry, we are fully prepared for the transition to RTU vials and cartridges,” said Lukas Burkhardt, Member of the Management Board of Gerresheimer AG. “With recent advancements, RTU processing is now a mature technology which will improve our customers operations in terms of efficiency, cost and time to market.”

The Alliance for RTU will be officially presented at the CPhI in Milan on October 8 during a dedicated event at the tradeshow fairground.

For more information, visit www.alliance-for-rtu.com.

About SCHOTT Pharma
Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of over 4,600 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the MDAX. It is part of SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 899 million in the fiscal year 2023. Further information at www.schott-pharma.com.

About Gerresheimer
Gerresheimer is an innovative systems and solutions provider and a global partner to the pharma, biotech, and cosmetics industries. The company offers a comprehensive portfolio of pharmaceutical containment solutions, drug delivery systems and medical devices as well as solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, ampoules, tablet containers, infusion, dropper and syrup bottles, and more. With 35 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. With around 12,000 employees, the company generated revenues of around €2bn in 2023. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6). www.gerresheimer.com

About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: stevanatogroup.com.


Press contact

SCHOTT Pharma
Media Relations
Joana Kornblum
Tel.: +49 151/29223552
E-Mail: joana.kornblum@schott.com
 
Investor Relations
Jasko Terzic, CFA
E-Mail: ir.pharma@schott.com

Gerresheimer AG
Media Relations
Jutta Lorberg
T +49 211 6181 264
E-Mail: jutta.lorberg@gerresheimer.com  

Investor Relations
Guido Pickert
Vice President Investor Relations
T +49 152 900 14145
E-Mail: gerresheimer.ir@gerresheimer.com

Stevanato Group
Media Relations
Stevanato Group
E-Mail: media@stevanatogroup.com
Cassie Gonzalez
E-Mail: stevanatoUS@teamlewis.com  

Investor Relations
Lisa Miles
E-Mail: lisa.miles@stevanatogroup.com



26.09.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: SCHOTT Pharma AG & Co. KGaA
Hattenbergstraße 10
55122 Mainz
Germany
ISIN: DE000A3ENQ51
WKN: A3ENQ5
Indices: MDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
EQS News ID: 1995693

 
End of News EQS News Service

1995693  26.09.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1995693&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2018 2019 2020 2021 2022 2023 2024e
Sales1 0,00 0,00 584,23 648,67 821,14 898,60 957,09
EBITDA1,2 0,00 0,00 131,94 164,10 219,73 239,00 257,55
EBITDA-Margin3 0,00 0,00 22,58 25,30 26,76 26,60 26,91
EBIT1,4 0,00 0,00 98,22 127,66 164,38 192,38 192,58
EBIT-Margin5 0,00 0,00 16,81 19,68 20,02 21,41 20,12
Net Profit (Loss)1 0,00 0,00 77,63 101,17 125,85 151,93 150,35
Net-Margin6 0,00 0,00 13,29 15,60 15,33 16,91 15,71
Cashflow1,7 0,00 0,00 104,40 132,21 182,12 181,65 225,33
Earnings per share8 0,00 0,00 0,51 0,67 0,83 1,01 0,99
Dividend per share8 0,00 0,00 0,00 0,00 0,12 0,15 0,18
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: Ernst & Young

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Schott Pharma
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
A3ENQ5 DE000A3ENQ51 AG & Co. KGaA 3.662,95 Mio € 28.09.2023 9F2C268V+9J
* * *
PE 2025e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
22,52 28,92 0,78 28,68 4,78 16,26 3,83
Dividends
Dividend '2022
in €
Dividend '2023
in €
Dividend '2024e
in €
Div.-Yield '2024e
in %
0,12 0,15 0,18 0,74%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
04.02.2025 13.02.2025 15.05.2025 12.08.2025 12.12.2024
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
+1,08%
24,32 €
ATH 42,40 €
-14,06% -23,83% -27,62% -27,19% -9,93%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2024          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2024 by Gereon Kruse #BGFL